

# **Influenza Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Ribavirin, Oseltamivir, Relenza, Peramivir, Influenza Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel), By Region, and Competition**

<https://marketpublishers.com/r/I80E6E0A78E0EN.html>

Date: November 2023

Pages: 185

Price: US\$ 4,900.00 (Single User License)

ID: I80E6E0A78E0EN

## **Abstracts**

Global Influenza Drugs Market has valued at USD 878.45 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.72% through 2028. Influenza is a common viral infection that, if not carefully and rapidly treated, can be deadly. It affects the nose, throat, and lungs badly and is an infectious respiratory infection. The best way to prevent the flu, which is brought on by influenza viruses, is to be vaccinated annually. Runny nose, exhaustion, aches in the muscles, headaches, fever, and congestion are the most typical influenza symptoms. The key factors driving the market growth is increasing incidence and prevalence of influenza, rising healthcare expenditure worldwide, and increasing awareness and concern for public health that anticipated to support the market growth during forecast period 2023-2030.

Moreover, the increasing prevalence of influenza can have several implications that may contribute to the growth of the Influenza Drugs Market. As the number of influenza cases rises, there anticipated to be an increased demand for medications to alleviate symptoms and reduce the severity of the illness. This increased demand can drive pharmaceutical companies to develop and market new and more effective influenza drugs. According to a World Health Organisation study performed from January 24 to February 6, 2022, around 12,368 persons tested positive with influenza viruses. Of

them, 8,423 (68.1%) were diagnosed with influenza A and 3,945 (31.9%) with influenza B. Furthermore, 171 (6.4%) were infected with influenza A (H1N1), whereas 2,483 (93.6%) were infected with influenza A (H3N2). Additionally, rise in R&D investments for discovery of new drugs is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of drug development, and side effects associated with antiviral therapy stifles market growth throughout the forecast period of 2023-2030.

## Ky Market Drivers

### Animal disease outbreaks

Antiviral demand is a significant driver in the Influenza Drugs Market, underlining the critical role of these medications in the prevention and treatment of influenza. Influenza, commonly known as the flu, is a highly contagious respiratory illness caused by influenza viruses, and it poses a substantial public health threat. Antiviral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) are the cornerstone of influenza treatment. They work by inhibiting the replication of the influenza virus in the body. When administered promptly after symptom onset, these antiviral medications can reduce the severity and duration of influenza symptoms. Antivirals not only alleviate the discomfort associated with the flu but also play a critical role in preventing severe complications, especially in high-risk populations like the elderly, young children, and individuals with underlying health conditions. These drugs can significantly lower the risk of hospitalization and death. In the event of an influenza pandemic, antiviral drugs become a frontline defense. Stockpiling these medications is a crucial part of pandemic preparedness strategies, as they can help mitigate the spread of the virus and reduce the burden on healthcare systems. The demand for antiviral drugs is global, as influenza is a ubiquitous and seasonally recurrent illness affecting populations in both hemispheres. This consistent demand ensures a stable market for influenza antivirals.

Pharmaceutical companies continue to invest in research and development to improve the effectiveness of existing antiviral drugs and to develop new antiviral agents with enhanced properties, further driving market growth.

Government health agencies often provide guidelines and recommendations for the use of antiviral medications during influenza outbreaks, contributing to increased demand and usage. In conclusion, antiviral demand is a pivotal driver in the Influenza Drugs Market due to the essential role these medications play in treating influenza, preventing complications, and preparing for potential pandemics. The continued focus on antiviral

development and their widespread use in healthcare systems worldwide ensure that this segment remains a cornerstone of influenza management and public health initiatives.

### Vaccination strategies

Vaccination strategies are a driving force in the Influenza Drugs Market, significantly influencing its dynamics and growth. Influenza vaccines are a critical component of public health efforts to prevent and mitigate the impact of influenza, and their adoption and distribution play a pivotal role in the market. Influenza vaccines are administered annually to populations worldwide as part of seasonal vaccination campaigns. This annual demand for vaccines ensures a consistent market for manufacturers and distributors. Vaccination strategies are implemented globally, making influenza vaccines accessible and necessary for populations in both developed and developing countries. This widespread reach contributes to a substantial market size. Vaccination strategies prioritize high-risk groups, including the elderly, young children, pregnant women, and individuals with underlying health conditions. These populations are more vulnerable to severe influenza-related complications, driving demand for vaccines tailored to their needs. Influenza vaccines are integral to pandemic preparedness. In the event of a novel influenza virus with pandemic potential, vaccine development and distribution become top priorities, bolstering the market.

Vaccine manufacturers continually invest in research and development to enhance vaccine efficacy, broaden protection against various influenza strains, and improve the vaccine's suitability for different age groups. This commitment to innovation drives market growth. Governments and public health agencies worldwide actively promote influenza vaccination as a preventive measure, often launching awareness campaigns and subsidizing vaccination costs. These initiatives contribute to increased vaccine uptake. The availability of healthcare infrastructure, such as vaccination clinics and healthcare providers, is crucial for successful vaccination campaigns. Investments in healthcare systems support vaccine distribution.

Ongoing global surveillance of influenza strains guides vaccine formulation, ensuring that vaccines are effective against prevalent strains each season. In summary, vaccination strategies are a primary driver for the Influenza Drugs Market, underlining the importance of preventive measures in managing influenza. The annual demand for vaccines, their global reach, and their role in pandemic preparedness, combined with research and development efforts and government support, collectively contribute to the sustained growth of this market segment.

## Key Market Challenges

### Antiviral resistance

Antiviral resistance presents a significant challenge for the Influenza Drugs Market. Influenza viruses have a remarkable ability to mutate rapidly, which can lead to the emergence of strains that are less susceptible to antiviral medications. This phenomenon, known as antiviral resistance, can compromise the effectiveness of commonly used drugs like oseltamivir (Tamiflu) and zanamivir (Relenza). Antiviral resistance can render these medications less effective in treating influenza, diminishing their role in managing the disease. Patients may experience prolonged illness and an increased risk of complications, undermining the value of antiviral treatment. The development and spread of antiviral-resistant strains raise public health concerns. These strains can potentially lead to more severe influenza outbreaks and increased hospitalizations, placing additional burdens on healthcare systems. Antiviral resistance can complicate pandemic preparedness efforts. Stockpiling antiviral drugs in preparation for a potential influenza pandemic may be less effective if the circulating strain becomes resistant, necessitating the development of alternative treatment strategies.

Addressing antiviral resistance requires ongoing research and development efforts to develop new antiviral agents that are effective against resistant strains. This can be resource-intensive for pharmaceutical companies. Continuous surveillance and monitoring of influenza strains are essential to detect and respond to antiviral resistance promptly. This requires coordinated efforts between healthcare agencies and research institutions. In conclusion, antiviral resistance poses a multifaceted challenge for the Influenza Drugs Market. It not only impacts the efficacy of current treatments but also necessitates ongoing research, surveillance, and preparedness to address emerging resistant strains. Mitigating this challenge is crucial to ensure that antiviral drugs remain effective tools in managing influenza and safeguarding public health.

### Strain mismatch with vaccine formulations.

Strain mismatch with vaccine formulations is a significant challenge in the Influenza Drugs Market and has several implications for influenza prevention and treatment. Influenza viruses frequently undergo genetic changes, leading to the emergence of new strains. If the strains included in a seasonal influenza vaccine do not closely match the circulating strains, the vaccine's effectiveness diminishes. This can result in a higher rate of vaccine failure, as individuals may still contract influenza despite being

vaccinated. Strain mismatch can lead to increased influenza infection rates within communities, which can strain healthcare systems and lead to a surge in hospitalizations. It also increases the risk of severe complications and mortality associated with the disease. Accurate strain prediction is essential for pandemic preparedness. If vaccine formulations consistently fail to match emerging pandemic strains, it hampers the effectiveness of vaccination campaigns during a global outbreak. Repeated instances of strain mismatch can erode public confidence in influenza vaccination. This may result in decreased vaccine uptake rates and a higher susceptibility to influenza outbreaks. Preparing and distributing vaccines is resource intensive. A mismatch between vaccine formulations and circulating strains can lead to wasted resources and efforts.

Vaccine manufacturers must constantly monitor circulating strains and adapt vaccine formulations accordingly. This requires significant investment in research and development to keep pace with the evolving nature of the influenza virus. Addressing the challenge of strain mismatch involves improving strain prediction methods and advancing vaccine development technologies, such as the development of universal influenza vaccines that provide broader protection against multiple strains. This ongoing challenge underscores the importance of continued research and collaboration within the healthcare and pharmaceutical sectors to enhance the effectiveness of influenza prevention and treatment strategies.

## Key Market Trends

### Universal influenza vaccines

Universal influenza vaccines are emerging as a prominent trend in the Influenza Drugs Market, representing a transformative shift in the approach to influenza prevention and treatment. These vaccines are designed to provide broad and long-lasting protection against multiple strains of influenza viruses, transcending the need for annual vaccine updates that specifically target predicted strains. Several factors are driving the trend of universal influenza vaccines:

The influenza virus is notorious for its ability to mutate and generate new strains. Universal vaccines aim to overcome this challenge by targeting conserved regions of the virus that are less prone to mutation, providing immunity against a broader spectrum of influenza strains. Universal vaccines have the potential to greatly reduce the strain mismatch issue that often occurs with seasonal vaccines. By offering protection against a wider range of strains, they mitigate the impact of unexpected influenza outbreaks and

improve overall vaccine efficacy. Universal vaccines can play a crucial role in pandemic preparedness. In the event of a novel influenza strain with pandemic potential, these vaccines offer a more comprehensive defense, as they are not dependent on accurate strain prediction.

The shift away from annual vaccinations to less frequent universal vaccines can improve vaccine compliance and convenience for individuals and healthcare systems, reducing the burden of annual vaccination campaigns. The development of universal influenza vaccines requires extensive research and collaboration among scientists and pharmaceutical companies. This trend fuels innovation in the field and stimulates investments in advanced vaccine technologies.

The widespread adoption of universal vaccines has the potential to significantly reduce the global burden of influenza, lowering infection rates, hospitalizations, and mortality associated with the disease. As awareness grows regarding the benefits of universal vaccines, patients may increasingly prefer these options over traditional seasonal vaccines, further driving their adoption. In conclusion, universal influenza vaccines represent a paradigm shift in influenza prevention, offering broader and longer-lasting protection against the ever-evolving influenza virus. This trend has the potential to revolutionize the Influenza Drugs Market by addressing longstanding challenges and improving the overall public health response to influenza outbreaks and pandemics.

### Telehealth for flu diagnosis and treatment

Telehealth for flu diagnosis and treatment is emerging as a significant trend in the Influenza Drugs Market, reshaping how healthcare providers and patients approach influenza management. This trend is driven by several factors and is poised to have a lasting impact on how influenza is diagnosed, treated, and prevented:

Telehealth platforms allow patients to consult with healthcare providers remotely, reducing the need for in-person clinic visits. This is especially beneficial during flu seasons when the risk of virus transmission in healthcare settings is high. Telehealth enables quicker diagnosis of influenza by facilitating virtual consultations. Patients can connect with healthcare professionals promptly, receive symptom assessments, and discuss treatment options without delay. Many telehealth platforms offer prescription services, allowing providers to electronically prescribe antiviral medications like Tamiflu. Patients can then obtain these drugs from local pharmacies, streamlining the treatment process. Telehealth alleviates the burden on healthcare facilities and emergency rooms, which are often overwhelmed during flu outbreaks. Patients with mild to moderate

symptoms can receive care without adding to the strain on the healthcare system.

Telehealth promotes continuity of care, ensuring that individuals receive prompt attention and follow-up care if needed. This contributes to better patient outcomes and reduces the likelihood of severe complications. Some telehealth platforms incorporate remote monitoring of patients with influenza. Healthcare providers can track patients' progress, adjust treatment plans, and intervene if symptoms worsen. Telehealth can be used to provide preventive education and vaccination information to patients. Healthcare professionals can encourage individuals to get vaccinated against influenza, enhancing public health efforts.

Telehealth improves access to care, especially for individuals in remote or underserved areas. Patients can receive timely medical advice without traveling long distances. Telehealth infrastructure supports rapid response and coordination during influenza pandemics. It allows for efficient triaging, monitoring, and treatment of patients on a large scale. In conclusion, the integration of telehealth into influenza diagnosis and treatment is a transformative trend in the Influenza Drugs Market. It enhances patient access to care, reduces healthcare burdens during flu seasons, and strengthens pandemic preparedness efforts. As technology and telehealth platforms continue to evolve, their role in influenza management is expected to expand, making healthcare more convenient, efficient, and responsive to the needs of patients.

## Segmental Insights

### Drug Type Insights

Based on the Drug Type, Influenza vaccines hold dominance in the Influenza Drugs Market for several compelling reasons. These vaccines are at the forefront of global efforts to prevent influenza and mitigate its impact: Influenza vaccines are primarily preventive, aiming to reduce the incidence and severity of influenza infections. This proactive approach aligns with public health strategies to curb the spread of the virus. Influenza vaccines are administered through extensive global vaccination campaigns. Governments, healthcare providers, and public health agencies promote and distribute these vaccines widely, ensuring broad accessibility and usage. The need for annual vaccination due to evolving influenza strains generates a consistent and substantial demand for influenza vaccines. This annual cycle guarantees a stable market. Influenza vaccines have a strong track record of efficacy in preventing influenza-related hospitalizations and deaths, particularly in high-risk populations. The adaptability of influenza vaccines to seasonal variations in influenza strains makes them a vital tool for

seasonal influenza preparedness, helping to minimize the impact of outbreaks.

Influenza vaccines also play a crucial role in pandemic preparedness. Manufacturers can pivot quickly to develop vaccines targeting emerging pandemic strains. Influenza vaccines have a well-established safety profile, instilling confidence in both healthcare providers and patients. Public awareness campaigns promote influenza vaccination as a routine preventive measure, further bolstering vaccine uptake. Preventing influenza through vaccination reduces healthcare costs associated with influenza treatment and lost productivity due to illness. Overall, influenza vaccines dominate the Influenza Drugs Market because they are a proven, cost-effective, and accessible means of preventing influenza and its complications. Their role in seasonal and pandemic preparedness, coupled with their safety and effectiveness, ensures their continued significance in influenza management and public health strategies worldwide.

### Distribution Channel Insights

Hospital pharmacies play a dominant role in the Influenza Drugs Market due to their strategic position within the healthcare ecosystem and their unique capacity to administer, store, and distribute influenza-related pharmaceuticals: Hospital pharmacies serve as central hubs for the distribution of influenza vaccines and antiviral drugs. They can efficiently coordinate the procurement and allocation of these drugs to healthcare facilities and clinics. Hospitals experience a high volume of patient visits, particularly during flu seasons, making them prime locations for administering influenza vaccines and initiating antiviral treatments promptly.

Hospital pharmacists are well-trained healthcare professionals who possess expertise in medication management. They can offer patients and healthcare providers guidance on appropriate antiviral medications and vaccine choices. Hospital pharmacies ensure timely access to antiviral medications for patients with severe influenza symptoms or complications, reducing the risk of hospitalization and severe outcomes.

Many hospitals have affiliated outpatient clinics and primary care facilities where influenza vaccines are administered, extending their reach to the community. Hospitals are critical in pandemic preparedness efforts, stockpiling antiviral medications and vaccines to respond swiftly in case of a widespread influenza outbreak. Hospital pharmacies adhere to strict quality control measures, ensuring the integrity and effectiveness of the influenza drugs they dispense. Hospital pharmacies collaborate closely with healthcare providers to implement vaccination programs and ensure that antiviral treatments are administered according to clinical guidelines. Hospital



pharmacies often engage in patient education initiatives, raising awareness about the importance of influenza vaccination and antiviral treatment. In summary, hospital pharmacies are dominant in the Influenza Drugs Market because they offer a centralized, accessible, and trusted avenue for the distribution and administration of influenza-related pharmaceuticals. Their role is pivotal in ensuring that patients receive timely treatment and preventive care during flu seasons, contributing to improved public health outcomes.

## Regional Insights

North America commands dominance in the Influenza Drugs Market for several compelling reasons: North America boasts a well-developed healthcare infrastructure with robust hospital systems, clinics, and pharmacies. This infrastructure facilitates efficient distribution, administration, and management of influenza drugs. The region places a strong emphasis on public health, with extensive awareness campaigns promoting influenza vaccination. Government and healthcare organizations actively encourage seasonal flu shots, fostering a culture of preventive healthcare. North America leads in research and development for influenza drugs and vaccines. Numerous pharmaceutical companies headquartered in the region continuously innovate to improve existing medications and develop novel treatments. Given its experience with previous pandemics, North America is highly prepared for potential influenza pandemics. Stockpiling of antiviral drugs and rapid response plans are well-established, ensuring a prompt and effective response. North America consistently achieves high influenza vaccination coverage rates, with many individuals opting for annual flu shots. This results in a substantial market for both vaccines and antiviral drugs. The region has stringent regulatory standards for drug approvals, enhancing the credibility and safety of influenza medications available in the market.

North American healthcare institutions collaborate with pharmaceutical companies and government agencies to conduct influenza research and clinical trials, contributing to the development of innovative drugs and vaccines. North America is home to several leading pharmaceutical companies with a global presence. Their commitment to influenza research and their capacity for large-scale production contribute significantly to market dominance. In summary, North America's dominance in the Influenza Drugs Market stems from its well-established healthcare infrastructure, proactive public health initiatives, strong research and development capabilities, and high vaccine coverage rates. These factors collectively position the region as a leader in influenza prevention, treatment, and pandemic preparedness.

## Key Market Players

FACCUSA Laboratories Inc

Lonza Group Ltd

Bristol-Myers Squibb Co

Pfizer Inc.

GlaxoSmithKline plc

Novo Nordisk A/S

Sanofi S.A

Bayer AG

Banting Medical Inc

Cipla Limited

## Report Scope:

In this report, the Global Influenza Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### Influenza Drugs Market, By Drug Type:

Ribavirin

Oseltamivir

Relenza

Peramivir

Influenza Vaccines

## Influenza Drugs Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Channel

## Influenza Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Influenza Drugs Market.

Available Customizations:

Global Influenza Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL INFLUENZA DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Drug Type (Ribavirin, Oseltamivir, Relenza, Peramivir, Influenza Vaccines)
  - 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel)
  - 5.2.3. By Region

- 5.2.4. By Company (2022)
- 5.3. Market Map

## **6. NORTH AMERICA INFLUENZA DRUGS MARKET OUTLOOK**

### 6.1. Market Size & Forecast

- 6.1.1. By Value

### 6.2. Market Share & Forecast

- 6.2.1. By Drug Type
- 6.2.2. By Distribution Channel
- 6.2.3. By Country

### 6.3. North America: Country Analysis

#### 6.3.1. United States Influenza Drugs Market Outlook

##### 6.3.1.1. Market Size & Forecast

- 6.3.1.1.1. By Value

##### 6.3.1.2. Market Share & Forecast

- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Distribution Channel

#### 6.3.2. Canada Influenza Drugs Market Outlook

##### 6.3.2.1. Market Size & Forecast

- 6.3.2.1.1. By Value

##### 6.3.2.2. Market Share & Forecast

- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Distribution Channel

#### 6.3.3. Mexico Influenza Drugs Market Outlook

##### 6.3.3.1. Market Size & Forecast

- 6.3.3.1.1. By Value

##### 6.3.3.2. Market Share & Forecast

- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Distribution Channel

## **7. EUROPE INFLUENZA DRUGS MARKET OUTLOOK**

### 7.1. Market Size & Forecast

- 7.1.1. By Value

### 7.2. Market Share & Forecast

- 7.2.1. By Drug Type
- 7.2.2. By Distribution Channel
- 7.2.3. By Country

### 7.3. Europe: Country Analysis

#### 7.3.1. Germany Influenza Drugs Market Outlook

##### 7.3.1.1. Market Size & Forecast

###### 7.3.1.1.1. By Value

##### 7.3.1.2. Market Share & Forecast

###### 7.3.1.2.1. By Drug Type

###### 7.3.1.2.2. By Distribution Channel

#### 7.3.2. United Kingdom Influenza Drugs Market Outlook

##### 7.3.2.1. Market Size & Forecast

###### 7.3.2.1.1. By Value

##### 7.3.2.2. Market Share & Forecast

###### 7.3.2.2.1. By Drug Type

###### 7.3.2.2.2. By Distribution Channel

#### 7.3.3. Italy Influenza Drugs Market Outlook

##### 7.3.3.1. Market Size & Forecast

###### 7.3.3.1.1. By Value

##### 7.3.3.2. Market Share & Forecast

###### 7.3.3.2.1. By Drug Type

###### 7.3.3.2.2. By Distribution Channel

#### 7.3.4. France Influenza Drugs Market Outlook

##### 7.3.4.1. Market Size & Forecast

###### 7.3.4.1.1. By Value

##### 7.3.4.2. Market Share & Forecast

###### 7.3.4.2.1. By Drug Type

###### 7.3.4.2.2. By Distribution Channel

#### 7.3.5. Spain Influenza Drugs Market Outlook

##### 7.3.5.1. Market Size & Forecast

###### 7.3.5.1.1. By Value

##### 7.3.5.2. Market Share & Forecast

###### 7.3.5.2.1. By Drug Type

###### 7.3.5.2.2. By Distribution Channel

## 8. ASIA-PACIFIC INFLUENZA DRUGS MARKET OUTLOOK

### 8.1. Market Size & Forecast

#### 8.1.1. By Value

### 8.2. Market Share & Forecast

#### 8.2.1. By Drug Type

#### 8.2.2. By Distribution Channel

### 8.2.3. By Country

## 8.3. Asia-Pacific: Country Analysis

### 8.3.1. China Influenza Drugs Market Outlook

#### 8.3.1.1. Market Size & Forecast

##### 8.3.1.1.1. By Value

#### 8.3.1.2. Market Share & Forecast

##### 8.3.1.2.1. By Drug Type

##### 8.3.1.2.2. By Distribution Channel

### 8.3.2. India Influenza Drugs Market Outlook

#### 8.3.2.1. Market Size & Forecast

##### 8.3.2.1.1. By Value

#### 8.3.2.2. Market Share & Forecast

##### 8.3.2.2.1. By Drug Type

##### 8.3.2.2.2. By Distribution Channel

### 8.3.3. Japan Influenza Drugs Market Outlook

#### 8.3.3.1. Market Size & Forecast

##### 8.3.3.1.1. By Value

#### 8.3.3.2. Market Share & Forecast

##### 8.3.3.2.1. By Drug Type

##### 8.3.3.2.2. By Distribution Channel

### 8.3.4. South Korea Influenza Drugs Market Outlook

#### 8.3.4.1. Market Size & Forecast

##### 8.3.4.1.1. By Value

#### 8.3.4.2. Market Share & Forecast

##### 8.3.4.2.1. By Drug Type

##### 8.3.4.2.2. By Distribution Channel

### 8.3.5. Australia Influenza Drugs Market Outlook

#### 8.3.5.1. Market Size & Forecast

##### 8.3.5.1.1. By Value

#### 8.3.5.2. Market Share & Forecast

##### 8.3.5.2.1. By Drug Type

##### 8.3.5.2.2. By Distribution Channel

## 9. SOUTH AMERICA INFLUENZA DRUGS MARKET OUTLOOK

### 9.1. Market Size & Forecast

#### 9.1.1. By Value

### 9.2. Market Share & Forecast

#### 9.2.1. By Drug Type



- 9.2.2. By Distribution Channel
- 9.2.3. By Country
- 9.3. South America: Country Analysis
  - 9.3.1. Brazil Influenza Drugs Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Drug Type
      - 9.3.1.2.2. By Distribution Channel
  - 9.3.2. Argentina Influenza Drugs Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Drug Type
      - 9.3.2.2.2. By Distribution Channel
  - 9.3.3. Colombia Influenza Drugs Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value
    - 9.3.3.2. Market Share & Forecast
      - 9.3.3.2.1. By Drug Type
      - 9.3.3.2.2. By Distribution Channel

## **10. MIDDLE EAST AND AFRICA INFLUENZA DRUGS MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Drug Type
  - 10.2.2. By Distribution Channel
  - 10.2.3. By Country
- 10.3. MEA: Country Analysis
  - 10.3.1. South Africa Influenza Drugs Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Drug Type
      - 10.3.1.2.2. By Distribution Channel
  - 10.3.2. Saudi Arabia Influenza Drugs Market Outlook
    - 10.3.2.1. Market Size & Forecast

- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
  - 10.3.2.2.1. By Drug Type
  - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Influenza Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Distribution Channel

## **11. MARKET DYNAMICS**

- 11.1. Drivers & Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisition

## **13. GLOBAL INFLUENZA DRUGS MARKET: SWOT ANALYSIS**

## **14. COMPETITIVE LANDSCAPE**

- 14.1. FACCUSA Laboratories Inc
  - 14.1.1. Business Overview
  - 14.1.2. Treatment Offerings
  - 14.1.3. Recent Developments
  - 14.1.4. Key Personnel
  - 14.1.5. SWOT Analysis
- 14.2. Lonza Group Ltd
- 14.3. Bristol-Myers Squibb Co
- 14.4. Pfizer Inc.
- 14.5. GlaxoSmithKline plc
- 14.6. Novo Nordisk A/S
- 14.7. Sanofi S.A
- 14.8. Bayer AG
- 14.9. Banting Medical Inc

14.10. Cipla Limited

**15. STRATEGIC RECOMMENDATIONS**

**16. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Influenza Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Ribavirin, Oseltamivir, Relenza, Peramivir, Influenza Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel), By Region, and Competition

Product link: <https://marketpublishers.com/r/I80E6E0A78E0EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I80E6E0A78E0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970